Serum levels of fibrin(ogen) degradation products (FDP) have been used since 1961 (Ferreira and Murat, 1961) in the diagnosis and treatment of both disseminated and local intravascular coagulation. Fibrinogen and fibrin are degraded by the fibrinolytic enzyme system to produce a heterogeneous series of degradation products of decreasing molecular weight: only the earliest products in the chain retain the ability to clot (Marder et al, 1969) . When FDP levels are measured in serum only the non-clottable molecules will be present, all others having been removed during coagulation. In preparing serum samples for the measurement of FDP it is essential to ensure that coagulation is complete; if it is not, the measured FDP levels will be falsely raised due to the persistence of clottable molecules. It is equally important to prevent activation of the fibrinolytic enzyme system during coagulation as this could also lead to an increase in levels in vitro. With these problems in mind, several workers have suggested conditions for the collection and preparation of serum samples for FDP determinations (table I) .
FDP levels can be measured by a variety of immunological techniques including haemagglutination inhibition (Merskey et al, 1966) , latex particle agglutination (Allington, 1971) , immunoelectrophoresis (Nilehn and Nillson, 1964) , and Received for publication 28 July 1975 radioimmunoassay (Gordon et al, 1973; 1975a; Plow and Edgington, 1973) . The radioimmunoassay method has the advantages of high sensitivity and precision, and is thus well suited to the study of variables in sample collection and preparation. In the present study a number of these variables have been examined in detail.
Material and Methods
All blood samples were collected into plastic syringes using minimal venous occlusion. The samples were aliquoted into glass tubes containing either (1) no additive, (2) 10 mg/ml amino caproic acid solution (EACA, Kabi Pharmaceuticals), (3) 250 Kallikrein inactivator units/ml aprotinin solution (Trasylol, Bayer Pharmaceuticals), (4) 10 mg/ml freeze-dried soybean trypsin inhibitor and 10 NIH units/ml thrombin (Wellcome Reagents), (5) 10 NIH units/ml of freshly suspended thrombin (Parke Davis Ltd) and 10 mg/ml EACA, (6) as (5) but stored at 20°C for 7 days, (7) 
Discussion
There is only one previous si optimal conditions for the cl samples for FDP assay have bee key et al, 1972) . In the present ins of conditions have been evaluat of diagnostic value FDP level reflect circulating degradation p artefact due to either incomplh version or to activation of the Activation of the coagulation sys tact with glass will activate the plasmin. The extent of plasmin as the degree of activation and the tii exposure. Although naturally inhibitors are found in blood, p] concentrated within the fibrin m( the effects of these inhibitors (Mc 1972) . In addition to plasmin, proteases including trypsin are a fibrin molecule (Latallo et al, 1' results described here would in( degradation of fibrin is mainl3
Thus EACA, which is a specifil (Brockway and Castellino, 1971) . inhibited FDP formation in v specific protease inhibitors (aprc trypsin inhibitor) produced only Activation of the fibrinolytic system occurs despite the presence of EACA when whole blood is incubated at 37°C for 24 hours. The presence of fibrin is essential since the effect is not seen with separated serum, as previously shown by Merskey and his coworkers (1972) .
Optimal activation of the contact factors (XI, XII) of the coagulation system in vitro depends on a number of factors including time, temperature, calcium concentrations, and glass in contact with the blood (Nossel, 1972 fibrin polymer of molecular weight greater than that of fibrinogen. These polymers contain partly degraded fibrinogen as judged by the ability of normal serum to cross react in the radioimmunoassay for the neoantigen of fragment D which is specific for the degradation products of fibrin(ogen) (Gordon et al, 1975b) . The presence of additional tudy in which the exogenous thrombin probably completes the coaguollection of serum lation of these partially degraded, high molecular en examined (Mers-weight fragments, whether added before or after vestigation a variety separation of the serum. However, from the point ted in detail. To be of view of routine use, the disadvantage of thrombin Is in serum should addition is that the solution cannot be freeze-dried ,roducts and not an nor can it be stored at room temperature. The use of ete fibrinogen con-thrombin should probably be confined to those fibrinolytic system. patients on anticoagulant therapy. In the present tem in vitro by con-study, the findings of Merskey and his coworkers fibrinolytic enzyme (1972) that thrombin will cause an elevation of ction will depend on FDP levels has not been confirmed. This discrepme and temperature ancy may perhaps be explained by the lack of occurring plasmin sensitivity and precision of the tanned red cell lasmin is selectively haemagglutination inhibition assay used in the esh and may escape previous study.
Nicol and Douglas,
Venous occlusion has been shown previously a number of other to cause a rise in the serum levels of FgE related to Lble to degrade the the rise in haematocrit and therefore due to haemo-971). However, the concentration (Butler et al, 1975) . dicate that in vitro
In conclusion, the optimum procedure for the y due to plasmin. collection of blood for FDP assay is as follows: c plasmin inhibitor samples should be taken using minimal venous , almost completely occlusion into glass tubes containing 10 mg/ml of vitro, whereas less EACA and allowed to clot at 4°C to 20°C for )tinin and soybean at least 4 hours before centrifugation. The serum partial inhibition. may be stored at either 4°C or -20°C. Samples from patients receiving anticoagulant therapy should be treated with 10 units of thrombin per ml of blood.
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